AbbVie’s First Profit Forecast is Higher Than Estimates

AbbVie Inc. forecast 2013 earnings higher than analysts’ estimates, after sales surged for its arthritis treatment Humira, the world’s second-best selling medicine, and its testosterone-boosting gel.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.